2022
Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Seminars In Immunopathology 2022, 44: 547-564. PMID: 35415765, PMCID: PMC9256560, DOI: 10.1007/s00281-022-00935-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBile acidsLiver diseaseTherapeutic targetAutoimmune liver diseaseCholestatic liver diseaseBile acid receptorAbsorption of lipidsFat-soluble vitaminsLiver inflammationInflammatory diseasesImmunomodulatory propertiesAcid receptorsInflammationDiseaseReceptorsClinical applicationLiverNutrient metabolismPathway
2021
The Neglected Role of Bile Duct Epithelial Cells in NASH
Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021, 42: 034-047. PMID: 34794182, DOI: 10.1055/s-0041-1739455.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisLiver diseaseInsulin resistancePrevalent liver diseaseBile duct epithelial cellsFatty liver diseaseSubset of patientsCommon pathogenetic mechanismDuct epithelial cellsMultiple biological effectsFibro-inflammationHepatic manifestationNAFLD patientsPortal fibrosisMetabolic syndromeBile ductDuctular reactionDisease progressionPathogenetic mechanismsLiver cancerMetabolic alterationsProgenitor cell compartmentEpithelial cellsDiseaseUnmet needs in basic and translational research in Cholangiocarcinoma
Cadamuro M, Macias R, Strain A, Strazzabosco M, Simioni P, Marin J, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2021, 3: 5-16. DOI: 10.1002/lci2.39.Peer-Reviewed Original ResearchTranslational researchManagement of cholangiocarcinomaTumor-restraining functionsSystematic literature searchCCA managementPoor prognosisExtrahepatic cholangiocarcinomaDeep molecular phenotypingConsensus statementEnigmatic diseaseActionable mutationsCholangiocarcinomaAccurate biomarkersTumor microenvironmentLiterature searchExperimental modelEarly detectionMarked heterogeneityDiseaseMolecular phenotypingWide heterogeneityFurther studiesTumorsMolecular characterization studiesComplex roleFibrocystic liver disease: novel concepts and translational perspectives
Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M. Fibrocystic liver disease: novel concepts and translational perspectives. Translational Gastroenterology And Hepatology 2021, 6: 26-26. DOI: 10.21037/tgh-2019-rld-13.Peer-Reviewed Original Research
2019
Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota
Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 197-207. PMID: 31075352, PMCID: PMC6664222, DOI: 10.1016/j.jcmgh.2019.04.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCF-associated liver diseaseLiver diseaseCystic fibrosisInnate immunityCystic fibrosis liver diseaseEpithelial innate immunityCystic fibrosis transmembrane conductance regulatorFibrosis transmembrane conductance regulatorNonpulmonary causesCF adultsTransmembrane conductance regulatorLiver complicationsMutations of CFTRPediatric populationAltered microbiotaIntestinal diseaseBile secretionCF mortalityDiseaseNew drugsConductance regulatorPotential targetLife expectancyBasic defectPathophysiology
2018
Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases
Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2018, 1865: 920-928. PMID: 30264693, PMCID: PMC6658095, DOI: 10.1016/j.bbadis.2018.08.038.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLiver diseaseStem cell fieldHepatocyte-like cellsPluripotent stem cellsRegenerative medicineNext-generation toolsSurvival of patientsRecent technological advancesMononuclear blood cellsPotential applicationsGene editingQuality of lifeLiver cell typesDisease modelingCell fieldAdequate cellular modelsLiver transplantationOrgan failureLiver specimensDiseaseStem cellsBlood cellsLiver cellsDrug testingSkin fibroblastsAnimal models of cholestasis: An update on inflammatory cholangiopathies
Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L. Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2018, 1865: 954-964. PMID: 30398152, DOI: 10.1016/j.bbadis.2018.07.025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnimal modelsPro-fibrotic signalsChronic liver diseasePrimary biliary cholangitisBile duct ligationFrequent clinical conditionBiliary injuryBiliary cholangitisBiliary obstructionLiver diseaseBiliary epitheliumDuct ligationInflammatory cholangiopathyAdaptive immunityClinical conditionsControversial diseasePathogenetic sequenceCholangiopathyCholestasisExperimental modelCholangitisDiseasePrimary targetChemical inductionCell elementsAnimal models for cystic fibrosis liver disease (CFLD)
Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2018, 1865: 965-969. PMID: 30071276, PMCID: PMC6474816, DOI: 10.1016/j.bbadis.2018.07.026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCystic fibrosis liver diseaseLiver diseaseAnimal modelsCF animal modelsCystic fibrosisEpithelial innate immunityMore specific treatmentsNovel therapeutic treatmentsDifferent animal modelsLiver manifestationsSevere complicationsPathogenetic factorSpecific treatmentCF miceGut microbiotaInnate immunityTherapeutic treatmentLiver phenotypeDiseaseChloride channelsCystic fibrosis transmembrane conductance regulator (CFTR) channelCFTR expressionHuman diseasesTreatmentApical membraneFibropolycystic Liver Diseases and Congenital Biliary Abnormalities
Hadžić N, Strazzabosco M. Fibropolycystic Liver Diseases and Congenital Biliary Abnormalities. 2018, 308-327. DOI: 10.1002/9781119237662.ch16.Peer-Reviewed Original ResearchFibropolycystic liver diseaseLiver diseasePolycystic kidney diseaseKidney diseaseAutosomal recessive polycystic kidney diseaseAutosomal dominant polycystic kidney diseaseFibrotic liver diseasePolycystic liver diseaseRecessive polycystic kidney diseaseDominant polycystic kidney diseaseCongenital biliary abnormalitiesBiliary microhamartomasPathogenetic pointCholedochal cystBiliary tractBiliary abnormalitiesBile ductCystic lesionsRenal abnormalitiesClinical reasonsCongenital anomaliesLiver parenchymaDiseaseHeterogeneous groupAbnormalitiesAnimal models of cholangiocarcinoma: What they teach us about the human disease
Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Animal models of cholangiocarcinoma: What they teach us about the human disease. Clinics And Research In Hepatology And Gastroenterology 2018, 42: 403-415. PMID: 29753731, DOI: 10.1016/j.clinre.2018.04.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnimal modelsNovel therapeutic approachesRelevant animal modelsPathogenesis of cholangiocarcinomaBiliary carcinogenesisTreatment optionsTherapeutic approachesRodent modelsLethal cancersClinical phenotypeExperimental modelCholangiocarcinomaAggressive behaviorCell interactionsHuman diseasesComplex cell biologyMultiple cell interactionsMolecular perturbationsPathogenesisTumorsCancerDiseaseCarcinogenesis
2017
Difference in health related quality of life of chronic liver diseases and general population
Cortesi P, Conti S, Scalone L, Ciaccio A, Okolicsanyi S, Rota M, Belli L, Cesana G, Strazzabosco M, Mantovani L. Difference in health related quality of life of chronic liver diseases and general population. European Journal Of Public Health 2017, 27: ckx187.078. DOI: 10.1093/eurpub/ckx187.078.Peer-Reviewed Original ResearchThe Healthy Biliary Tree: Cellular and Immune Biology
Cadamuro M, Fabris L, Strazzabosco M. The Healthy Biliary Tree: Cellular and Immune Biology. 2017, 17-41. DOI: 10.1007/978-3-319-50168-0_2.Peer-Reviewed Original ResearchBiliary innate immunityToll-like receptorsPathogen-associated molecular patternsBiliary treeLiver diseaseCystic fibrosis-related liver diseaseInnate immunityCystic fibrosis liver diseaseAntigen-presenting cellsBiliary epithelial cellsLiver injuryBile ductBiliary diseaseLiver damageInflammatory responseImmune biologyFirst defense lineProinflammatory behaviorSecretory activityMolecular patternsCholangiocytesEpithelial cellsDiseaseCholangiopathyEvidence highlights
2015
Oxidative Stress in Nonautoimmune Biliary Diseases
Cadamuro M, Fabris L, Strazzabosco M. Oxidative Stress in Nonautoimmune Biliary Diseases. Oxidative Stress In Applied Basic Research And Clinical Practice 2015, 309-324. DOI: 10.1007/978-3-319-15539-5_13.Peer-Reviewed Original Research
2013
Notch signaling and new therapeutic options in liver disease
Morell CM, Strazzabosco M. Notch signaling and new therapeutic options in liver disease. Journal Of Hepatology 2013, 60: 885-890. PMID: 24308992, DOI: 10.1016/j.jhep.2013.11.028.Peer-Reviewed Original ResearchConceptsLiver diseaseTherapeutic agentsNew therapeutic optionsNotch signalingSpecific therapeutic agentsStem cell featuresTherapeutic optionsLiver malignanciesLiver metabolismTherapeutic relevanceAberrant activationLiver regenerationPersistent activationDiseaseAdult liverPossible targetsFurther studiesCell featuresNovel findingsRecent reportsNotch pathwayLiverCritical playersSignalingActivationProtein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis
Spirli C, Locatelli L, Morell CM, Fiorotto R, Morton SD, Cadamuro M, Fabris L, Strazzabosco M. Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology 2013, 58: 1713-1723. PMID: 23744610, PMCID: PMC3800498, DOI: 10.1002/hep.26554.Peer-Reviewed Original ResearchConceptsAutosomal recessive polycystic kidney diseaseCongenital hepatic fibrosisCaroli's diseaseΒ-cateninHepatic fibrosisRac-1 inhibitionIntrahepatic bile ductsRecessive polycystic kidney diseasePotential therapeutic targetPolycystic kidney diseaseStimulation of cAMPRac-1 activityE-cadherin expressionBile ductKidney diseaseLiver pathologyCystic dysplasiaMouse modelTherapeutic targetTranscriptional activityNuclear translocationDiseasePKA blockerCholangiocytesFibrosisNonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion?
Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion? Hepatology 2013, 58: 819-821. PMID: 23703812, DOI: 10.1002/hep.26498.Peer-Reviewed Original Research
2012
Polycystic liver diseases
Fabris L, McCrann C, Strazzabosco M. Polycystic liver diseases. 2012, 713-718. DOI: 10.1002/9781118321386.ch96.ChaptersPolycystic liver diseaseLiver diseaseCongenital hepatic fibrosisAutosomal dominant polycystic liver diseaseDifferent clinical entitiesChronic complicationsKidney involvementLiver transplantationPortal hypertensionCaroli's diseaseMedical therapyClinical entityLiver functionMultiple cystsSurgical approachHepatic fibrosisBiliary epitheliumHepatic parenchymaLiver parenchymaProgressive enlargementInterventional radiologyDiseaseGenetic defectsEndoplasmic reticulum-associated proteinParenchymaDevelopment of the bile ducts: Essentials for the clinical hepatologist
Strazzabosco M, Fabris L. Development of the bile ducts: Essentials for the clinical hepatologist. Journal Of Hepatology 2012, 56: 1159-1170. PMID: 22245898, PMCID: PMC3328609, DOI: 10.1016/j.jhep.2011.09.022.Peer-Reviewed Original ResearchConceptsLiver diseaseBile ductBiliary structuresFibropolycystic liver diseaseExtrahepatic biliary treeBiliary developmentLiver repair mechanismsHepatocellular damageBiliary treeDuctular reactionLiver repairReparative responseAlagille syndromePathogenic aspectsClinical hepatologistsCholangiopathyGrowth factorParacrine signalsEmbryonic lifeDiseaseDuctRepair mechanismsHepatologistsSyndromeTranscription factors
2011
Polycystic Liver Diseases: Congenital Disorders of Cholangiocyte Signaling
Strazzabosco M, Somlo S. Polycystic Liver Diseases: Congenital Disorders of Cholangiocyte Signaling. Gastroenterology 2011, 140: 1855-1859.e1. PMID: 21515270, PMCID: PMC3109236, DOI: 10.1053/j.gastro.2011.04.030.Peer-Reviewed Original ResearchConceptsPolycystic liver diseaseLiver cyst formationClinical featuresLiver diseaseMultiple cystsDisease progressionBiliary epitheliumLiver parenchymaProgressive enlargementCongenital diseaseCyst formationCholangiocyte physiologyCongenital disorderPotential targetGenetic defectsDiseaseProgressionDisordersInheritance patternSignalingIntracellular organellesDifferent entitiesTherapyKidneyPathway
2008
Type I Autoimmune Hepatitis Presenting With Acute Liver Failure in the Setting of Wild Mushroom Ingestion
Rogart JN, Iyer A, Robert ME, Levy G, Strazzabosco M. Type I Autoimmune Hepatitis Presenting With Acute Liver Failure in the Setting of Wild Mushroom Ingestion. Journal Of Clinical Gastroenterology 2008, 42: 662-666. PMID: 18496396, PMCID: PMC3762257, DOI: 10.1097/mcg.0b013e3181595b7c.Peer-Reviewed Original ResearchConceptsAcute liver failureAutoimmune hepatitisLiver failureType I Autoimmune HepatitisWild mushroom ingestionIndolent presentationInitial manifestationEnvironmental antigensSeventh decadeMushroom ingestionUnusual caseSusceptible individualsHepatitisYoung womenAge rangeDiseaseType IWomenFailureEtiologyAntigenIngestion